[HTML][HTML] An intranasally administered adenovirus-vectored SARS-CoV-2 vaccine induces robust mucosal secretory IgA

B Sun, Q Wang, P Zheng, X Niu, Y Feng, W Guan… - JCI …, 2024 - pmc.ncbi.nlm.nih.gov
BACKGROUND The level of nasal spike-specific secretory IgA (sIgA) is inversely correlated
with the risk of SARS-CoV-2 Omicron infection. This study aimed to evaluate the safety and …

COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA within the oronasopharynx of young children

Y Tang, BP Boribong, ZN Swank… - The Journal of …, 2024 - academic.oup.com
Background Understanding antibody responses to SARS-CoV-2 vaccination is crucial for
refining COVID-19 immunization strategies. Generation of mucosal immune responses …

Meeting Report From “Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID‐19 Pandemic”

F Krammer, JM Katz, OG Engelhardt… - Influenza and Other …, 2024 - Wiley Online Library
Background This report summarizes the discussions and conclusions from the “Correlates of
Protection for Next Generation Influenza Vaccines: Lessons Learned from the COVID‐19 …

Viral and immune profiles during the first wave of SARS-CoV-2 infection in hospitalized patients in Sardinia, Italy

G Venturi, A Gallinaro, C Fortuna, MF Pirillo… - Scientific Reports, 2025 - nature.com
We performed a retrospective immunological analysis of the antibody response in serum
and in nasopharyngeal swabs (NPS) obtained from 46 individuals infected with ancestral …

[HTML][HTML] Safety and efficacy of RCP recombinant spike protein covid-19 vaccine compared to Sinopharm BBIBP: A phase III, non-inferiority trial

M Solaymani-Dodaran, S Kalantari, SR Banihashemi… - Heliyon, 2024 - cell.com
Background We conducted a phase III, non-inferiority trial comparing safety and efficacy of
RCP recombinant spike protein Covid-19 vaccine to BBIBP (Sinopharm). Methods Adult …

An Engineered SARS-CoV-2 S1 Glycoprotein Produced in Pichia pastoris as a Candidate Vaccine Antigen

S Majidi, K Aghaiypour Kolyani, M Akrami… - Molecular …, 2025 - Springer
Abstract Since December 2019, the SARS-CoV-2 virus has caused the global COVID-19
pandemic. Antiviral and anti-inflammatory treatments have had limited success, positioning …

[HTML][HTML] Epithelial Antimicrobial Peptide/Protein and Cytokine Expression Profiles Obtained from Nasopharyngeal Swabs of SARS-CoV-2-Infected and Non-Infected …

T Gambichler, S Goesmann, M Skrygan, L Susok… - Viruses, 2024 - mdpi.com
Immune responses of the epithelia of the upper respiratory tract are likely crucial in early
inhibition of the viral replication and finally clearance of SARS-CoV-2. We aimed to compare …